Quick Summary: Sandoz Shares Drop as US Announces Steep Generic Drug Tariffs
- The US plans to impose a 100% tariff on generic medicine imports starting August 2028, escalating to 200% if production doesn’t shift to the US.
- This marks a stark policy reversal from April 2026 when the White House exempted generics from tariffs while targeting patented drugs.
- Trump’s tariff threat aims to bring drug manufacturing back to the US, potentially leading to higher generic drug prices.
- Sandoz, a major generic-drug maker, has been directly impacted, with its shares dropping 3% following the announcement.
- The policy shift could heavily affect production in China and India, where most generic drugs are currently manufactured.
Source: Open external resource
Source: Read original article
In a dramatic policy shift, the US government has announced plans to impose steep tariffs on generic medicine imports starting August 2028. This move, spearheaded by President Donald Trump, aims to incentivize pharmaceutical companies to relocate their manufacturing processes to the United States. The tariffs are set to start at 100% and could rise to 200% if companies fail to comply.
This decision marks a significant reversal from the White House’s April 2026 proclamation, which had initially exempted generics from tariffs while imposing a 100% duty on patented drugs. The abrupt policy change has sent shockwaves through the pharmaceutical industry, with companies like Sandoz already feeling the financial impact. Sandoz’s stock fell by 3% after the news broke, highlighting the market’s immediate reaction to the potential cost increases.
Trump’s administration justifies this aggressive tariff approach on national security grounds, arguing that too much of the US drug supply relies on foreign manufacturing. Currently, over 90% of medicines sold in the US are generics, and the majority are produced in countries like China and India. Critics warn that these tariffs could lead to significant price hikes for consumers, undermining the affordability of essential medications.
While the tariffs are intended to boost domestic production, the practical implications remain uncertain. Analysts like Stefan Schneider suggest that reversing the trend of offshoring drug production could have unintended economic consequences, including increased prices for generic drugs. As the policy process unfolds, the pharmaceutical industry and policymakers will continue to grapple with the potential fallout of this bold trade maneuver.
That is a striking escalation because the White House’s own April 2026 pharmaceutical tariff proclamation explicitly said the administration had decided “not to adjust imports of generic pharmaceuticals and their associated ingredients” at that time, even as it imposed a 100% duty on many patented pharmaceutical imports. The administration’s earlier proclamation also set near-term dates for patented-drug duties — July 31, 2026 for companies listed in Annex III and September 29, 2026 for other importers — so the immediate next phase is that branded-pharma tariffs arrive within days, even while the generic-drug threat is deferred for two years.
Its shares fell about 3% after the market open on July 22, 2026, after Trump’s new tariff threat became public. In April, the White House carved generics out of the tariff regime; by July 21, 2026, Trump was posting that those same products would face one of the steepest tariff schedules yet announced in his trade campaign.
On July 21, 2026, Reuters reported Trump’s statement that imported generics would remain tariff-free for two years from August 1 before being hit with 100% and then 200% duties. The most newsworthy revelation from the latest reporting is the scale and timing of Trump’s threat: Reuters, echoed by Bloomberg pickups, reports that the tariff would stay at zero for two years from August 1 before rising to 100% from August 2028 and 200% starting the year after.
The big new turn in this story is that President Donald Trump has now moved beyond this spring’s tariff action on patented drugs and publicly threatened generic medicines too, saying imported generics will stay at 0% only until August 1, 2028, then jump to 100% for one year and 200% after that if manufacturers do not make them in the United States. Vontobel analyst Stefan Schneider, in the same reporting, said the administration appears to be trying to reverse the migration of generic-drug production to lower-cost countries, but warned that bringing that manufacturing back would likely raise generic-drug prices in the United States.
are generics, according to the FDA figure cited by Reuters, which is why the proposal immediately landed as more than a trade-policy skirmish. manufacturing site on Long Island, New York, around the end of 2026, and that it gets about 22% of sales from North America while having little production there.
In a dramatic policy shift, the US government has announced plans to impose steep tariffs on generic medicine imports starting August 2028. br) That is a striking escalation because the White House’s own April 2026 pharmaceutical tariff proclamation explicitly said the administration had decided “not to adjust imports of generic pharmaceuticals and their associated ingredients” at that time, even as it imposed a 100% duty on many patented pharmaceutical imports.
The administration’s earlier proclamation also set near-term dates for patented-drug duties — July 31, 2026 for companies listed in Annex III and September 29, 2026 for other importers — so the immediate next phase is that branded-pharma tariffs arrive within days, even while the generic-drug threat is deferred for two years. Its shares fell about 3% after the market open on July 22, 2026, after Trump’s new tariff threat became public.
In April, the White House carved generics out of the tariff regime; by July 21, 2026, Trump was posting that those same products would face one of the steepest tariff schedules yet announced in his trade campaign. On July 21, 2026, Reuters reported Trump’s statement that imported generics would remain tariff-free for two years from August 1 before being hit with 100% and then 200% duties.
Vontobel analyst Stefan Schneider, in the same reporting, said the administration appears to be trying to reverse the migration of generic-drug production to lower-cost countries, but warned that bringing that manufacturing back would likely raise generic-drug prices in the United States. Sandoz, a major generic-drug maker, has been directly impacted, with its shares dropping 3% following the announcement.
The tariffs are set to start at 100% and could rise to 200% if companies fail to comply. This decision marks a significant reversal from the White House’s April 2026 proclamation, which had initially exempted generics from tariffs while imposing a 100% duty on patented drugs.
The scale and speed of this development has caught many observers off guard. Each new update adds another dimension to a story that is still unfolding, and the full picture will only become clear as more verified details emerge from the people and institutions directly involved.
Analysts who have tracked this issue closely say the current moment represents a genuine turning point. The decisions made in the coming weeks are expected to set the direction for months ahead, with ripple effects likely to extend well beyond the immediate actors in the story.
For those directly affected, the practical impact is already visible. People navigating this fast-changing situation are dealing with real consequences while new information continues to reshape what is known and what remains open to interpretation.
Historical parallels offer some context, though experts caution against drawing too close a comparison. Similar situations have played out before, but the specific combination of pressures, personalities, and timing here makes this moment distinct in ways that matter for how it ultimately resolves.
The political and economic dimensions of this story are deeply intertwined. What appears as a single event on the surface is in practice the convergence of multiple pressures that have been building quietly over a longer period than most public reporting has captured.